How structural, physicochemical, pharmacokinetic and toxicological similarity to the API can support impurity qualification.
An impurity may sometimes be sufficiently similar to the active pharmaceutical ingredient that existing API safety data become informative. The conclusion should be based on integrated evidence rather than superficial structural resemblance.
Structural relationship
The impurity should be compared with the API at a chemically meaningful level.
Physicochemical properties
Differences in ionization, lipophilicity, solubility and other properties can alter biological behavior.
PK/ADME
Absorption, metabolism and clearance can affect whether API data are relevant to the impurity.
Toxicological consistency
The absence of new toxicophores or major changes in target-organ concern strengthens the argument.
Frequently asked questions
Does 'API-like' mean identical to the API?
No. It means the existing API data are scientifically informative for the impurity.
Is structural similarity alone enough?
No.
Why consider ADME?
Because structural changes can alter internal exposure and metabolite formation.
Can API-like reasoning avoid unnecessary testing?
Potentially, when the evidence robustly supports the conclusion.
